Blinder Victoria S相关文献与解析，生知库

Aiello Bowles, Erin J; O'Connell, Kelli; Bhimani, Jenna; Gallagher, Grace B; Blinder, Victoria S; Doud, Rachael Burganowski; Ergas, Isaac J; Griggs, Jennifer J; Heon, Narre; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Nakata, Kanichi G; Persaud, Sonia; Rivera, Donna R; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Wang, Peng; Bandera, Elisa V; Kushi, Lawrence H; Kantor, Elizabeth D

肿瘤

肿瘤免疫

乳腺癌

发表日期：2026

文献求助收藏

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer

与I-IIIA期乳腺癌化疗剂量减少相关的临床医生和医疗机构层面的因素

期刊:Jnci-Journal of the National Cancer Institute

影响因子:7.2

doi:10.1093/jnci/djag063

Sampathkumar, Yashasvini; Zakaria, Ziad; O'Connell, Kelli; Bhimani, Jenna; Blinder, Victoria S; Burganowski, Rachael; Ergas, Isaac J; Gallagher, Grace B; Griggs, Jennifer J; Heon, Narre; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Monroy-Iglesias, Maria J; Nakata, Kanichi G; Persaud, Sonia; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Wang, Peng; Bandera, Elisa V; Aiello Bowles, Erin J; Kushi, Lawrence H; Kantor, Elizabeth D

Provider billing margin and cancer treatment selection: population based cohort study

医疗服务提供者收费利润率与癌症治疗选择：基于人群的队列研究

期刊:Bmj-British Medical Journal

影响因子:42.7

doi:10.1136/bmj-2025-084729

Mitchell, Aaron P; Dusetzina, Stacie B; Mishra Meza, Akriti; Gallagher, Grace; Augello, Patrick; Fuchs, Hannah; Guzman, Gabrielle; Abdelaziz, Abdullah; Tabatabai, Sara; Persaud, Sonia; Chakraborty, Nirjhar; Blinder, Victoria S; Epstein, Andrew S; Daly, Bobby; Winn, Aaron N; Gönen, Mithat

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

了解体重指数与接受 I-IIIA 期乳腺癌治疗的女性化疗剂量减少之间的关系

期刊:NPJ Breast Cancer

影响因子:7.6

doi:10.1038/s41523-025-00833-9

Bhimani, Jenna; O'Connell, Kelli; Gallagher, Grace B; Blinder, Victoria S; Burganowski, Rachael; Ergas, Isaac J; Griggs, Jennifer J; Heon, Narre; Jinna, Sankeerth; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Nakata, Kanichi G; Persaud, Sonia; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Wang, Peng; Bandera, Elisa V; Aiello Bowles, Erin J; Kushi, Lawrence H; Kantor, Elizabeth D

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer

临床医生和医疗机构层面的因素与I-IIIA期乳腺癌女性接受非指南化疗方案相关

期刊:Jco Oncology Practice

影响因子:4.6

doi:10.1200/OP-25-00086

Sampathkumar, Yashasvini; Zakaria, Ziad; O'Connell, Kelli; Bhimani, Jenna; Blinder, Victoria S; Burganowski, Rachael; Ergas, Isaac J; Gallagher, Grace B; Griggs, Jennifer J; Heon, Narre; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Nakata, Kanichi G; Persaud, Sonia; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Bandera, Elisa V; Aiello Bowles, Erin J; Kushi, Lawrence H; Kantor, Elizabeth D

Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment

接受根治性治疗的在职乳腺癌幸存者运动启动和参与趋势

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-024-07526-0

Oza, Sonal; Patil, Sujata; Sampathkumar, Yashasvini; Gany, Francesca; Blinder, Victoria S

Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer

I-IIIA期乳腺癌女性患者接受常规化疗方案与高剂量密集化疗方案的患者特征

期刊:Breast Cancer Research and Treatment

影响因子:3

doi:10.1007/s10549-025-07764-w

Bhimani, Jenna; Wang, Peng; Gallagher, Grace B; O'Connell, Kelli; Persaud, Sonia; Blinder, Victoria S; Burganowski, Rachael; Ergas, Isaac J; Griggs, Jennifer J; Heon, Narre; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Nakata, Kanichi G; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Bandera, Elisa V; Aiello Bowles, Erin J; Kushi, Lawrence H; Kantor, Elizabeth D

Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)

确定患者报告结局版不良事件通用术语标准 (PRO-CTCAE®) 中病情恶化的有意义的个体水平变化阈值

期刊:Quality of Life Research

影响因子:2.7

doi:10.1007/s11136-024-03819-5

Lee, Minji K; Mitchell, Sandra A; Basch, Ethan; Mazza, Gina L; Langlais, Blake T; Thanarajasingam, Gita; Ginos, Brenda F; Rogak, Lauren; Meek, Eric A; Jansen, Jennifer; Deal, Allison M; Carr, Philip; Blinder, Victoria S; Jonsson, Mattias; Mody, Gita N; Mendoza, Tito R; Bennett, Antonia V; Schrag, Deborah; Dueck, Amylou C

发表日期：2025

文献求助收藏

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial

利用电子患者报告结局监测癌症治疗期间的症状：PRO-TECT 整群随机试验的最终结果

期刊:Nature Medicine

影响因子:

doi:10.1038/s41591-025-03507-y

Basch, Ethan; Schrag, Deborah; Jansen, Jennifer; Henson, Sydney; Ginos, Brenda; Stover, Angela M; Carr, Philip; Spears, Patricia A; Jonsson, Mattias; Deal, Allison M; Bennett, Antonia V; Thanarajasingam, Gita; Rogak, Lauren; Reeve, Bryce B; Snyder, Claire; Bruner, Deborah; Cella, David; Kottschade, Lisa A; Perlmutter, Jane; Geoghegan, Cindy; Given, Barbara; Mazza, Gina L; Miller, Robert; Strasser, Jon F; Zylla, Dylan M; Weiss, Anna; Blinder, Victoria S; Wolf, Anna P; Dueck, Amylou C

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

奥拉帕尼辅助治疗乳腺癌伴生殖系BRCA1/2突变患者的成本效益分析

期刊:Jama Network Open

影响因子:9.7

doi:10.1001/jamanetworkopen.2023.50067

Zettler, Christina M; De Silva, Dilanka L; Blinder, Victoria S; Robson, Mark E; Elkin, Elena B

Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer

年龄与I-IIIA期乳腺癌女性化疗剂量减少之间的关联

Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer

与I-IIIA期乳腺癌化疗剂量减少相关的临床医生和医疗机构层面的因素

Provider billing margin and cancer treatment selection: population based cohort study

医疗服务提供者收费利润率与癌症治疗选择：基于人群的队列研究

Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

了解体重指数与接受 I-IIIA 期乳腺癌治疗的女性化疗剂量减少之间的关系

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer

临床医生和医疗机构层面的因素与I-IIIA期乳腺癌女性接受非指南化疗方案相关

Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment

接受根治性治疗的在职乳腺癌幸存者运动启动和参与趋势

Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I-IIIA breast cancer

I-IIIA期乳腺癌女性患者接受常规化疗方案与高剂量密集化疗方案的患者特征

Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)

确定患者报告结局版不良事件通用术语标准 (PRO-CTCAE®) 中病情恶化的有意义的个体水平变化阈值

Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial

利用电子患者报告结局监测癌症治疗期间的症状：PRO-TECT 整群随机试验的最终结果

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

奥拉帕尼辅助治疗乳腺癌伴生殖系BRCA1/2突变患者的成本效益分析